The Use of Olanzapine Versus Metoclopramide for the Treatment of Breakthrough Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Highly Emetogenic Chemotherapy

被引：0
|
作者：
Navari, Rudolph [1 ,2 ]
Nagy, Cindy [1 ]
Gray, Sarah [2 ]
机构：
[1] Indiana Univ Sch Med, South Bend, IN USA
[2] Univ Notre Dame, Notre Dame, IN 46556 USA
来源：
PSYCHO-ONCOLOGY | 2013年 / 22卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
下载
收藏
页码：31 / 31
页数：1
相关论文
共 50 条
  • [21] A Pragmatic Study Evaluating NEPA Versus Aprepitant for Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Moderately Emetogenic Chemotherapy
    Zelek, Laurent
    Debourdeau, Philippe
    Bourgeois, Hugues
    Wagner, Jean Philippe
    Brocard, Fabien
    Lefeuvre-Plesse, Claudia
    Chauffert, Bruno
    Leheurteur, Marianne
    Bachet, Jean-Baptiste
    Simon, Helene
    Mayeur, Didier
    Scotte, Florian
    ONCOLOGIST, 2021, 26 (10): : E1870 - E1879
  • [22] Olanzapine for the prevention and treatment of chronic nausea and chemotherapy-induced nausea and vomiting
    Navari, Rudolph M.
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2014, 722 : 180 - 186
  • [23] Palonosetron Prevents Highly Emetogenic Chemotherapy-induced Nausea and Vomiting in Oral Cancer Patients
    Sento, Shinya
    Kitamura, Naoya
    Yamamoto, Tetsuya
    Nakashiro, Koichi
    Hamakawa, Hiroyuki
    Ibaragi, Soichiro
    Sasaki, Akira
    Takamaru, Natsumi
    Miyamoto, Yoji
    Kodani, Isamu
    Ryoke, Kazuo
    Mishima, Katsuaki
    Ueyama, Yoshiya
    ANTICANCER RESEARCH, 2017, 37 (12) : 6977 - 6981
  • [24] Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting
    Navari, Rudolph M.
    Qin, Rui
    Ruddy, Kathryn J.
    Liu, Heshan
    Powell, Steven F.
    Bajaj, Madhuri
    Dietrich, Leah
    Biggs, David
    Lafky, Jacqueline M.
    Loprinzi, Charles L.
    NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (02): : 134 - 142
  • [25] Rolapitant for the prevention of chemotherapy-induced nausea and vomiting in breast cancer patients receiving multiple cycles of emetogenic chemotherapy
    Schwartzberg, L.
    Navari, R.
    Arora, S.
    Powers, D.
    Jordan, K.
    Rapoport, B.
    CANCER RESEARCH, 2017, 77
  • [26] Olanzapine for chemotherapy-induced nausea and vomiting control
    Tsuruta, Seiji
    Matsuguma, Kunihito
    Kawasaki, Naruaki
    Ishikawa, Ayaka
    Ishiki, Hiroto
    LANCET ONCOLOGY, 2024, 25 (05): : e176 - e176
  • [27] CLINICAL RESEARCH OF OLANZAPINE FOR PREVENTION OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING RESISTANT TO STANDARD ANTIEMETIC THERAPY FOR HIGHLY EMETOGENIC CHEMOTHERAPY.
    Abe, M.
    Kasamatsu, Y.
    Ooi, T.
    Komeda, S.
    Kuji, S.
    Tanaka, A.
    Takahashi, N.
    Takekuma, M.
    Hirashima, Y.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2014, 24 (09) : 1271 - 1271
  • [28] Efficacy and safety of palonosetron as salvage treatment in the prevention of chemotherapy-induced nausea and vomiting in patients receiving low emetogenic chemotherapy (LEC)
    Paul J. Hesketh
    Gary Morrow
    Anna W. Komorowski
    Raza Ahmed
    David Cox
    Supportive Care in Cancer, 2012, 20 : 2633 - 2637
  • [29] Efficacy and safety of palonosetron as salvage treatment in the prevention of chemotherapy-induced nausea and vomiting in patients receiving low emetogenic chemotherapy (LEC)
    Hesketh, Paul J.
    Morrow, Gary
    Komorowski, Anna W.
    Ahmed, Raza
    Cox, David
    SUPPORTIVE CARE IN CANCER, 2012, 20 (10) : 2633 - 2637
  • [30] The use of olanzapine compared to aprepitant as antiemetic for prevention of chemotherapy induced nausea and vomiting in highly emetogenic chemotherapy - a randomized trial
    Sapkota, S.
    Mahaseth, R.
    Jha, K.
    EUROPEAN JOURNAL OF CANCER, 2017, 72 : S168 - S168
12345